Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22308290 | 0.79 | CYP2C9 (0.35) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL824013 | 0.78 | — | — | |
| SCHEMBL3255442 | 0.78 | CYP2C9 (0.41) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL20756433 | 0.78 | CPA1 (0.40) | CPB2 | |
| SCHEMBL19788788 | 0.78 | CPB2 (0.38) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL28805941 | 0.75 | CPA1 (0.31) | CPB2 | |
| SCHEMBL20921331 | 0.75 | — | — | |
| SCHEMBL26586063 | 0.75 | CYP2C9 (0.35) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL19780679 | 0.75 | CYP2C9 (0.35) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL4402850 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | WASHINGTON UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| US-20180066015-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | WASHINGTON UNIVERSITY (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2017161045-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-8586018-B1 | Thin films for controlled protein interaction | UNIV FLORIDA STATE RES FOUND (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130284600-A1 | THIN FILMS FOR CONTROLLED PROTEIN INTERACTION | UNIV FLORIDA STATE RES FOUND (US) | 2013-10-31 | — | — | US | disclosed |
| US-8481017-B2 | Thin films for controlled protein interaction | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-7722752-B2 | Variable charge films for controlling microfluidic flow | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | HDGF, MMP7, HGF | CYP2C9 1363/4885CYP2C19 1428/4885TSHR 1371/4885 |
| US-20180066015-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | HDGF, MMP7, HGF | CYP2C9 1363/4885CYP2C19 1428/4885TSHR 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.